Shares of vaccine companies, including Novavax, Inc. (NASDAQ:NVAX), are trading higher amid COVID-19 concerns due to rising cases in China.
Rising COVID-19 cases in China's capital Beijing and Shanghai, where enforcement of a strict "zero-COVID" policy is ongoing, have drawn global attention.
The world's second-largest economy has been struggling to completely stamp out the pandemic as traders and investors weigh increasing infections in the region.
See Also: Why Axsome Therapeutics Stock Is Falling Today
Novavax, a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs.
According to data from Benzinga Pro, Novavax has a 52-week high of $277.80 and a 52-week low of $46.03.
